Komori
Mti (9438) · InitiativeRestated

Capital and business alliance with メディパルホールディングス

First written in FY2016-Q3. 8 of 17 entries say "Restated". Latest entry: FY2025.

17entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016-Q3 – FY2017RestatedFY2019-Q2 – FY2019-Q32016: 120162017: 120172018: 120182019: 320192020: 020202021: 420212022: 320222023: 220232024: 120242025: 12025
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「Because dispensing pharmacies continue to show strong interest in adopting the cloud-based medication history system and it can contribute to sustainable revenue and profit growth in this business, the company will further expand the number of adopting stores by strengthening collaboration with its partner MEDIPAL HOLDINGS CORPORATION.」

    The company continues to pursue a policy of expanding the number of stores adopting cloud-based medication histories through strengthened collaboration with メディパル, thereby driving revenue and profit growth.
  2. FY2024AdvancedAnnual report

    「Because dispensing pharmacies continue to show strong interest in adopting the cloud-based medication history system and it can contribute to sustainable revenue and profit growth in this business, the company will further expand the number of adopting stores by strengthening collaboration with its partner MEDIPAL HOLDINGS CORPORATION.」

    The collaboration with メディパル is explicitly described not only as expanding the number of stores adopting cloud-based medication histories, but also as strengthening the partnership to achieve sustainable revenue and profit growth.
  3. FY2023RestatedAnnual report

    「Because adoption of the cloud-based medication history system is particularly strong among dispensing pharmacies and the system can contribute to sustainable revenue growth in the healthcare business, the company will further expand the number of adopting stores by strengthening collaboration with its partner MEDIPAL HOLDINGS CORPORATION.」

    The company continues to expand store adoption of the cloud-based medication history system through collaboration with Medipal as a measure to achieve sustainable growth in the healthcare business.
  4. FY2023-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 16 September 2022, the company resolved to sell part of its shares in its consolidated subsidiary 母子モ株式会社 to its consolidated subsidiary 株式会社エムティーアイ・ヘルスケア・ホールディングス, and transferred the shares on 20 October 2022.」

    The company transferred part of its shares in 母子モ to the intermediate healthcare holding company to integrate the 母子モ business, in which collaboration with Medipal is particularly strong.
  5. FY2022-Q3RestatedAnnual report

    「In the healthcare business, we collaborated with our partner MEDIPAL HOLDINGS CORPORATION both to expand the number of stores adopting the cloud-based medication history system, whose adoption at dispensing pharmacies has gained momentum, and to actively expand sales of childcare-related solutions, including maternal and child health handbook apps, to local governments.」

    The company continues to use its collaboration with Medipal to expand store adoption of the cloud-based medication history system and sales of childcare-related solutions to local governments.
  6. FY2022-Q2RestatedAnnual report

    「In the healthcare business, we collaborated with our partner MEDIPAL HOLDINGS CORPORATION both to expand the number of stores adopting the cloud-based medication history system, whose adoption at dispensing pharmacies has gained momentum, and to actively expand sales of childcare-related solutions, including maternal and child health handbook apps, to local governments.」

    The company continues to use its collaboration with Medipal to expand store adoption of the cloud-based medication history system and sales of childcare-related solutions to local governments.
  7. FY2022-Q1AdvancedAnnual report

    「Effective 1 July 2021, the company established 株式会社エムティーアイ・ヘルスケア・ホールディングス and plans to progressively consolidate into it the healthcare businesses of the company or its consolidated subsidiaries in which collaboration with Medipal is advancing. Because collaboration with Medipal is particularly strong in the maternal and child health handbook app business related to 母子モ, and consolidation into the new company is under consideration, the company decided to transfer this business to 母子モ.」

    The company is giving concrete form to the consolidation of healthcare businesses into an intermediate holding company by transferring the maternal and child health handbook app business, in which collaboration with Medipal is particularly strong, to 母子モ.
  8. FY2021AdvancedAnnual report

    「To promote the collaboration more closely and flexibly, the company determined that it would be effective to establish an intermediate holding company and consolidate the businesses in which the two companies have a high degree of collaboration.」

    The collaboration with Medipal progressed to a concrete organizational arrangement involving the establishment of an intermediate holding company and the consolidation of healthcare businesses with a high degree of collaboration.
  9. FY2021-Q3RestatedAnnual report

    「In the healthcare business, we collaborated with our partner MEDIPAL HOLDINGS CORPORATION both to expand the number of stores adopting the cloud-based medication history system, whose adoption at dispensing pharmacies has gained momentum following revisions to the medical reimbursement system, and to expand sales of childcare-related solutions, including maternal and child health handbook apps, to local governments.」

    The company continues to use its collaboration with Medipal to expand store adoption of the cloud-based medication history system and sales of childcare-related solutions.
  10. FY2021-Q2AdvancedAnnual report

    「Collaboration in the cloud-based medication history system business for dispensing pharmacies is the most advanced. The company will establish a structure that facilitates further collaboration with Medipal by transferring all shares of ソラミチ, which operates this business, from the company to カラダメディカ, a jointly funded company of the company and Medipal.」

    The collaboration with Medipal progressed to a concrete organizational arrangement involving the transfer of all ソラミチ shares to カラダメディカ and a ¥6,157 million capital increase through a shareholder allocation by カラダメディカ.
  11. FY2021-Q1AdvancedAnnual report

    「In the healthcare business, we collaborated with our partner MEDIPAL HOLDINGS CORPORATION and actively held online seminars to expand the number of stores adopting the cloud-based medication history system, whose adoption has gained momentum following revisions to the medical reimbursement system.」

    The existing collaboration with Medipal has developed into specific joint initiatives, including expanding store adoption of the cloud-based medication history system and holding online seminars.
  12. FY2019-Q3RestatedAnnual report

    「On 9 November 2018, the company's consolidated subsidiary カラダメディカ conducted a third-party capital increase allocated to MEDIPAL HOLDINGS CORPORATION and received total payment of ¥2,115 million. As a result, during the first nine months of the current fiscal year, capital surplus increased by ¥1,064.261 million」

    The third-party capital increase by カラダメディカ and Medipal's payment of ¥2,115 million were also confirmed as an increase in capital surplus in the third quarter.
  13. FY2019-Q2RestatedAnnual report

    「On 9 November 2018, the company's consolidated subsidiary カラダメディカ conducted a third-party capital increase allocated to MEDIPAL HOLDINGS CORPORATION and received total payment of ¥2,115 million. As a result, during the first six months of the current fiscal year, capital surplus increased by ¥1,064.261 million and, together with the ¥2.601 million increase from the issuance of new shares, stood at ¥6,887.550 million at the end of the second-quarter consolidated accounting period.」

    The third-party capital increase by カラダメディカ and Medipal's payment of ¥2,115 million continue to be disclosed as increases in capital surplus for the quarter.
  14. FY2019-Q1AchievedAnnual report

    「The company's consolidated subsidiary カラダメディカ conducted a third-party capital increase allocated to MEDIPAL HOLDINGS CORPORATION and received total payment of ¥2,115 million. As a result, during the first quarter of the current fiscal year, capital surplus increased by ¥1,064.261 million and, together with the ¥226,000 increase from the issuance of new shares, stood at ¥6,885.174 million at the end of the first-quarter consolidated accounting period.」

    The third-party capital increase by カラダメディカ, which had been given concrete form in the previous fiscal year, was carried out, and Medipal completed payment of ¥2,115 million.
  15. FY2018AdvancedAnnual report

    「In June 2016, the company and Medipal entered into a capital and business alliance aimed at promoting the adoption of ICT in the medical and healthcare fields and realizing the creation of a medical and healthcare platform. As part of advancing this alliance, the two companies agreed to collaborate on an online medical consultation services business. To further deepen their collaboration, the company's wholly owned subsidiary カラダメディカ will conduct a third-party capital increase allocated to Medipal, giving Medipal a 34.4% ownership interest.」

    The existing capital and business alliance with Medipal was given concrete form through a third-party capital increase by カラダメディカ and collaboration on online medical consultation services. The funds raised were ¥2,115 million, with payment made on 9 November 2018.
  16. FY2017RestatedAnnual report

    「MEDIPAL HOLDINGS CORPORATION 1,150,000 1.89」

    The capital relationship with Medipal Holdings continues to be listed in the shareholder composition.
  17. FY2016-Q3First statedAnnual report

    「At a meeting of the Board of Directors held on 7 June 2016, the company resolved to dispose of treasury shares through a third-party allotment to MEDIPAL HOLDINGS CORPORATION and, on the same date, entered into a share subscription agreement and a basic agreement on a capital and business alliance. Under the agreement, payment of ¥876.3 million was completed on 23 June 2016, and 1,150,000 treasury shares were disposed of.」

    The basic agreement on a capital and business alliance through the third-party allotment of treasury shares and completion of payment are disclosed.
Moved together

"Risks of Upfront Investment and Failure to Meet Plans in the Healthcare Services Business" moved the same way as this thread, in the same document, in 5 of its 17 moves.

554332★123456
  1. ★This thread
  2. 1Risks of Upfront Investment and Failure to Meet Plans in the Healthcare Services Business5×
  3. 2Expansion of installations of the Cloud Medication History system5×
  4. 3Resolution to Issue Stock Options for Directors and Employees4×
  5. 4Expansion of child-rearing solutions, including maternal and child health handbook apps, for local governments3×
  6. 5Investments in スタージェン and スマートメド3×
  7. 6Operating structure for the Life and Healthcare businesses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Mti's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.